William C. Shakespeare

7.1k total citations
59 papers, 3.2k citations indexed

About

William C. Shakespeare is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, William C. Shakespeare has authored 59 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 19 papers in Oncology and 18 papers in Organic Chemistry. Recurrent topics in William C. Shakespeare's work include Chronic Myeloid Leukemia Treatments (17 papers), Protein Kinase Regulation and GTPase Signaling (12 papers) and Chemical Synthesis and Analysis (9 papers). William C. Shakespeare is often cited by papers focused on Chronic Myeloid Leukemia Treatments (17 papers), Protein Kinase Regulation and GTPase Signaling (12 papers) and Chemical Synthesis and Analysis (9 papers). William C. Shakespeare collaborates with scholars based in United States, Spain and South Korea. William C. Shakespeare's co-authors include Victor M. Rivera, David C. Dalgarno, Tomi K. Sawyer, Yihan Wang, Tim Clackson, Chester A. Metcalf, Ralph Hirschmann, Richard P. Johnson, Raji Sundaramoorthi and Scott Wardwell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

In The Last Decade

William C. Shakespeare

59 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William C. Shakespeare United States	29	1.8k	933	816	666	546	59	3.2k
Judy Lucas United States	34	2.2k 1.3×	1000 1.1×	1.1k 1.3×	443 0.7×	261 0.5×	69	4.1k
James J. Gibbons United States	27	2.3k 1.3×	706 0.8×	613 0.8×	361 0.5×	509 0.9×	77	3.8k
Steven A. Middleton United States	30	1.8k 1.1×	1.2k 1.3×	798 1.0×	386 0.6×	373 0.7×	63	3.7k
Frank Boschelli United States	28	1.4k 0.8×	581 0.6×	654 0.8×	823 1.2×	128 0.2×	69	2.6k
Luca Mologni Italy	32	1.7k 1.0×	942 1.0×	267 0.3×	1.1k 1.6×	596 1.1×	91	3.4k
Peter Blume‐Jensen United States	18	3.3k 1.9×	1.3k 1.4×	250 0.3×	488 0.7×	561 1.0×	25	5.0k
Cho Tang United States	21	2.9k 1.7×	1.0k 1.1×	816 1.0×	280 0.4×	425 0.8×	29	4.3k
Steven W. Elmore United States	24	3.2k 1.8×	1.2k 1.3×	716 0.9×	510 0.8×	215 0.4×	37	4.8k
Carolyn Discafani United States	23	1.4k 0.8×	1.4k 1.5×	872 1.1×	205 0.3×	569 1.0×	30	3.0k
A Levitzki Israel	21	1.8k 1.0×	1.1k 1.2×	202 0.2×	395 0.6×	172 0.3×	26	3.1k

Countries citing papers authored by William C. Shakespeare

Since Specialization

Citations

This map shows the geographic impact of William C. Shakespeare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Shakespeare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Shakespeare more than expected).

Fields of papers citing papers by William C. Shakespeare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Shakespeare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Shakespeare. The network helps show where William C. Shakespeare may publish in the future.

Co-authorship network of co-authors of William C. Shakespeare

This figure shows the co-authorship network connecting the top 25 collaborators of William C. Shakespeare. A scholar is included among the top collaborators of William C. Shakespeare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Shakespeare. William C. Shakespeare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gozgit, Joseph M., Matthew J. Wong, Lauren Moran, et al.. (2012). Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. Molecular Cancer Therapeutics. 11(3). 690–699. 273 indexed citations

Zhang, Sen, Frank Wang, Jeffrey Keats, et al.. (2010). Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research. 70(8_Supplement). LB–298. 44 indexed citations

Azam, Mohammad, John T. Powers, William S. Einhorn, et al.. (2009). AP24163 Inhibits the Gatekeeper Mutant of BCR‐ABL and Suppresses In vitro Resistance. Chemical Biology & Drug Design. 75(2). 223–227. 18 indexed citations

Zhou, Tianjun, Lois Commodore, Wei‐Sheng Huang, et al.. (2009). Structural Analysis of DFG‐in and DFG‐out Dual Src‐Abl Inhibitors Sharing a Common Vinyl Purine Template. Chemical Biology & Drug Design. 75(1). 18–28. 23 indexed citations

Han, Liz Y., Charles N. Landen, José G. Treviño, et al.. (2006). Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Research. 66(17). 8633–8639. 68 indexed citations

Azam, Mohammad, William C. Shakespeare, Tomi K. Sawyer, & George Q. Daley. (2006). Targeted inhibition of Gatekeeper variant “T315I” of BCR-ABL by a purine based ATP-competitive inhibitor. Cancer Research. 66. 1139–1139. 1 indexed citations

Treviño, José G., Michael J. Gray, Steffan T. Nawrocki, et al.. (2006). Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis. 9(2). 101–110. 42 indexed citations

Boyce, Brendan F., Lianping Xing, Zhenqiang Yao, et al.. (2006). Future Anti‐Catabolic Therapeutic Targets in Bone Disease. Annals of the New York Academy of Sciences. 1068(1). 447–457. 18 indexed citations

Lesslie, Donald P., Justin M. Summy, Nila U. Parikh, et al.. (2006). Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. British Journal of Cancer. 94(11). 1710–1717. 101 indexed citations

10.

Azam, Mohammad, Valentina Nardi, William C. Shakespeare, et al.. (2006). Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences. 103(24). 9244–9249. 87 indexed citations

11.

Dalgarno, David C., Thilo Stehle, Surinder S. Narula, et al.. (2005). Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds. Chemical Biology & Drug Design. 67(1). 46–57. 65 indexed citations

12.

Sawyer, Tomi K., William C. Shakespeare, Raji Sundaramoorthi, et al.. (2005). Protein Phosphorylation and Signal Transduction Modulation: Chemistry Perspectives for Small-Molecule Drug Discovery. Medicinal Chemistry. 1(3). 293–319. 21 indexed citations

13.

Sundaramoorthi, Raji, William C. Shakespeare, Terence P. Keenan, et al.. (2003). Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Bioorganic & Medicinal Chemistry Letters. 13(18). 3063–3066. 14 indexed citations

14.

Sawyer, Tomi K., Regine S. Bohacek, David C. Dalgarno, et al.. (2002). Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide. Mini-Reviews in Medicinal Chemistry. 2(5). 475–488. 42 indexed citations

15.

Yang, Michael G., George P. Luke, William C. Shakespeare, et al.. (2001). A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphonophenylalanine (cpp): exploitation in the design of nonpeptide inhibitors of pp60Src SH2 domain. Bioorganic & Medicinal Chemistry Letters. 11(17). 2319–2323. 16 indexed citations

16.

Shakespeare, William C.. (2001). SH2 domain inhibition: a problem solved?. Current Opinion in Chemical Biology. 5(4). 409–415. 74 indexed citations

17.

Violette, Shelia M., William C. Shakespeare, Catherine Bartlett, et al.. (2000). A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chemistry & Biology. 7(3). 225–235. 47 indexed citations

18.

Shakespeare, William C., Regine S. Bohacek, Surinder S. Narula, et al.. (1999). An efficient synthesis of a 4′-phosphonodifluoromethyl-3′-formyl-phenylalanine containing Src SH2 ligand. Bioorganic & Medicinal Chemistry Letters. 9(21). 3109–3112. 10 indexed citations

19.

Rickles, Richard J., Wei Guan, Mihai Azimioara, et al.. (1998). A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitors. Chemistry & Biology. 5(10). 529–538. 6 indexed citations

20.

Shakespeare, William C. & Richard P. Johnson. (1990). 1,2,3-cyclohexatriene and cyclohexen-3-yne: two new highly strained C6H6 isomers. Journal of the American Chemical Society. 112(23). 8578–8579. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact